Therapeutic agents targeting ESR1 are now under phase 3 clinical trials in endometriosis (66), and thus, we further performed attack analysis in the context of AKT1 + ESR1, with maximal network disconnection (~16%) achieved by 3-node removal (Figure 6C). The gene discussed is ESR1; the disease is endometriosis.